Product Description
CXCR4-inhibitor (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01374503)
Mechanisms of Action: CXCR4 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alcoholism
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | P2 |
Not yet recruiting |
Alcoholism |
2022-09-01 |
|
ALX-0651-1.1/11 | P1 |
Terminated |
Healthy Volunteers |
2012-01-01 |